Prions are lethal infectious agents thought to consist of multi-chain forms (PrP(Sc)) of misfolded cellular prion protein (PrP(C)). Prion propagation proceeds in two distinct mechanistic phases: an exponential phase 1, which rapidly reaches a fixed level of infectivity irrespective of PrP(C) expression level, and a plateau (phase 2), which continues until clinical onset with duration inversely proportional to PrP(C) expression level. We hypothesized that neurotoxicity relates to distinct neurotoxic species produced following a pathway switch when prion levels saturate. Here we show a linear increase of proteinase K-sensitive PrP isoforms distinct from classical PrP(Sc) at a rate proportional to PrP(C) concentration, commencing at the phase transition and rising until clinical onset. The unaltered level of total PrP during phase 1, when prion infectivity increases a million-fold, indicates that prions comprise a small minority of total PrP. This is consistent with PrP(C) concentration not being rate limiting to exponential prion propagation and neurotoxicity relating to critical concentrations of alternate PrP isoforms whose production is PrP(C) concentration dependent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104459 | PMC |
| http://dx.doi.org/10.1038/ncomms5347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced poly(3-hydroxybutyrate-co-3-hydroxyvalerate) production from volatile fatty acids by Halomonas sp. YJ01 with 2-methylcitrate cycle.
J Environ Manage
January 2025
School of Environmental Science and Engineering, Zhejiang Gongshang University, Hangzhou, 310018, PR China; International Science and Technology Cooperation Platform for Low-Carbon Recycling of Waste and Green Development, Zhejiang Gongshang University, Hangzhou, 310012, PR China. Electronic address:
Volatile fatty acids (VFAs) are suitable substrates for synthesizing poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), wherein propionate is a precursor of PHBV biosynthesis; however, high concentrations are toxic to bacteria. Therefore, VFAs with suitable ratio are needed. Here, with the ratio of acetate: propionate: butyrate being 1:4:2, the maximum PHBV content and the 3HV content were 46.
View Article and Find Full Text PDFCopper binding alters the core structure of amyloid fibrils formed by Y145Stop human prion protein.
Phys Chem Chem Phys
October 2024
Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
Transmissible spongiform encephalopathies (or prion diseases) such as Creutzfeldt-Jacob disease, mad cow disease, and scrapie are characterized by accumulation in the brain of misfolded prion protein aggregates (PrP) that have properties of amyloid fibrils. Given that transition metal ions, such as copper and zinc, appear to be important for physiological functions of cellular PrP (PrP) as well as for prion disease pathogenesis, exploring their role in the protein aggregation process is of considerable interest. Copper(II) in particular is well-known to bind to the four tandem octapeptide repeats (PHGGGWGQ) located in the N-terminal region of PrP (human PrP amino acids 60-91), as well as to additional histidine binding sites outside the octarepeat region with distinct binding modes depending on Cu concentration.
View Article and Find Full Text PDFCellular Prion Protein Conformational Shift after Liquid-Liquid Phase Separation Regulated by a Polymeric Antagonist and Mutations.
J Am Chem Soc
October 2024
Departments of Neuroscience and Neurology, Yale School of Medicine, 100 College Street, New Haven, Connecticut 06510, United States.
Liquid-liquid phase separation (LLPS) of intrinsically disordered proteins has been associated with neurodegenerative diseases, although direct mechanisms are poorly defined. Here, we report on a maturation process for the cellular prion protein (PrP) that involves a conformational change after LLPS and is regulated by mutations and poly(4-styrenesulfonic acid--maleic acid) (PSCMA), a molecule that has been reported to rescue Alzheimer's disease-related cognitive deficits by antagonizing the interaction between PrP and amyloid-β oligomers (Aβo). We show that PSCMA can induce reentrant LLPS of PrP and lower the saturation concentration () of PrP by 100-fold.
View Article and Find Full Text PDFUpdate on a brain-penetrant cardiac glycoside that can lower cellular prion protein levels in human and guinea pig paradigms.
PLoS One
September 2024
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Lowering the levels of the cellular prion protein (PrPC) is widely considered a promising strategy for the treatment of prion diseases. Building on work that established immediate spatial proximity of PrPC and Na+, K+-ATPases (NKAs) in the brain, we recently showed that PrPC levels can be reduced by targeting NKAs with their natural cardiac glycoside (CG) inhibitors. We then introduced C4'-dehydro-oleandrin as a CG with improved pharmacological properties for this indication, showing that it reduced PrPC levels by 84% in immortalized human cells that had been differentiated to acquire neural or astrocytic characteristics.
View Article and Find Full Text PDFAdaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti-prion compounds.
FASEB J
July 2024
Department of Neurology, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Prion diseases result from the misfolding of the physiological prion protein (PrP) to a pathogenic conformation (PrP). Compelling evidence indicates that prevention and/or reduction of PrP replication are promising therapeutic strategies against prion diseases. However, the existence of different PrP conformations (or strains) associated with disease represents a major problem when identifying anti-prion compounds.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!